| scholarly article | Q13442814 |
| P50 | author | Juliane Haedicke | Q80785771 |
| P2093 | author name string | Thomas Iftner | |
| P2860 | cites work | European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document | Q24644710 |
| Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study | Q30278853 | ||
| Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study | Q30300943 | ||
| Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. | Q30423690 | ||
| High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study | Q30452935 | ||
| Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities | Q30456505 | ||
| HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review | Q33762996 | ||
| Chemiluminescent DNA probes: a comparison of the acridinium ester and dioxetane detection systems and their use in clinical diagnostic assays | Q33805872 | ||
| Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia | Q33978458 | ||
| Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer | Q34046296 | ||
| Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results | Q34298145 | ||
| The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies | Q34330297 | ||
| Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer | Q34596772 | ||
| Human papillomavirus and Papanicolaou tests to screen for cervical cancer | Q34702284 | ||
| Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology | Q34740980 | ||
| Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions | Q34995358 | ||
| Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). | Q46136299 | ||
| HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. | Q51824401 | ||
| American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer | Q57089342 | ||
| Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type | Q72992807 | ||
| Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial | Q79824170 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial | Q82586477 | ||
| Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets | Q84341096 | ||
| Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results | Q84554685 | ||
| Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3 | Q84748387 | ||
| Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study | Q84818275 | ||
| Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US) | Q84967041 | ||
| Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study | Q35108590 | ||
| Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test | Q35140046 | ||
| Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology | Q35193205 | ||
| Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities | Q35498040 | ||
| Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein | Q35614019 | ||
| Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? | Q35621096 | ||
| Detection and typing of human papillomavirus by e6 nested multiplex PCR | Q35716913 | ||
| Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany | Q35868702 | ||
| Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening | Q36395656 | ||
| Comparing the performance of six human papillomavirus tests in a screening population | Q36663594 | ||
| HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease | Q36856284 | ||
| A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States | Q36983254 | ||
| Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears | Q37310663 | ||
| Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older | Q37461977 | ||
| The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening | Q37470374 | ||
| Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening | Q37496183 | ||
| Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme | Q37516596 | ||
| Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid | Q37546570 | ||
| Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay | Q37713738 | ||
| Molecular diagnostic testing for infectious diseases using TMA technology | Q37872317 | ||
| The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy | Q38011639 | ||
| Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer | Q38064070 | ||
| Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types | Q38123772 | ||
| Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion | Q38408998 | ||
| Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. | Q39145081 | ||
| Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 | ||
| Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction | Q40495720 | ||
| The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology | Q40698187 | ||
| A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years | Q40933987 | ||
| High-risk HPV detection and genotyping by APTIMA HPV using cervical samples | Q41247169 | ||
| Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology | Q41633856 | ||
| Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens | Q41732609 | ||
| Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples | Q42218929 | ||
| Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care? | Q42237084 | ||
| Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). | Q42242703 | ||
| Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. | Q42245903 | ||
| Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay | Q42285883 | ||
| Analytical characterization of the APTIMA HPV Assay | Q43299397 | ||
| Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study | Q43769391 | ||
| Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion | Q44451879 | ||
| Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection | Q45139873 | ||
| Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S40-S48 | |
| P577 | publication date | 2015-11-06 | |
| P1433 | published in | Journal of Clinical Virology | Q15759726 |
| P1476 | title | A review of the clinical performance of the Aptima HPV assay | |
| P478 | volume | 76 Suppl 1 |
| Q91688493 | Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis |
| Q47631015 | Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women. |
| Q57035937 | Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities |
| Q90987623 | Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women |
| Q90657433 | Comparison of CerviHPV and Hybrid Capture 2 HPV tests for detection of high-risk HPV infection in cervical swab specimens |
| Q39013857 | Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types |
| Q36205998 | HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows |
| Q36675236 | Human Papillomavirus Laboratory Testing: the Changing Paradigm |
| Q57791055 | Human papillomaviruses other than 16, 18 and 45 are the major high risk HPV genotypes amongst women with abnormal cervical smear cytology residing in Kuwait: Implications for future vaccination strategies |
| Q88804925 | Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology |
| Q38752133 | Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg |
| Q39120200 | Molecular approaches for HPV genotyping and HPV-DNA physical status |
| Q91604699 | Oral testing for high-risk human papillomavirus DNA and E6/E7 messenger RNA in healthy individuals at risk for oral infection |
| Q38988920 | Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa |
| Q64056128 | Prevalence, correlates, and predictive value of high-risk human papillomavirus mRNA detection in a community-based cervical cancer screening program in western Uganda |
| Q90183581 | RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues |
| Q40636388 | Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. |
| Q57792215 | The longitudinal clinical performance of the RNA-based AHPV Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval in Germany |
| Q38824019 | Triage of high-risk HPV positive women in cervical cancer screening. |
| Q41935999 | Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? |
| Q90168285 | Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation |
Search more.